The findings of a new research shed light on the mechanisms by which gut bacteria influence the development and progression of multiple sclerosis.
René Kamminga, CEO of OptiBiotix: “OptiXOS is unlike any prebiotic fibre commercially available in Europe today".
The findings of a new research suggest that combining Lachnospiraceae antibody screening with blood tests could improve the diagnosis of ME/CFS.
BioAro is a biotechnology company redefining healthcare through genetic sequencing, AI development and blockchain technologies.
Chris Callewaert (Research Foundation Flanders - FWO) discussed the research he conducted on the effect of pollutants on skin microbiome and micobiome.
The findings of a new study suggest that the interplay between diet, microbiota and intestinal immunity regulates obesity, diabetes and other metabolic conditions.
Funds to be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand into new offerings and markets
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Marco Caspani, Chief Executive Officer at CSL Srl, discussed the challenges and the opportunity of producing anaerobic bacteria during the press conference on The Akkermansia Company.
Michael Oredsson, CEO at The Akkermansia Company, discussed with the new postbiotic supplement containing pastorised Akkermansia muciniphila.
